Company news
Transgene Sa (EURONEXT:TNG) news
Transgene Sa news releases on 6ix. Latest, Oct 5, 2026: Transgene Will Present a Poster on Preclinical Data from a Novel Oncolytic Virus at SITC 2026
Press releases & updates
Transgene Will Present a Poster on Preclinical Data from a Novel Oncolytic Virus at SITC 2026
October 5, 2026
Transgene to Participate in Investor Access
October 1, 2026
Transgene participera à l’Investor Access
September 30, 2026
Transgene Extends its myvac® Platform, Further Establishing its Position as a Key Player in the Rapidly Emerging Individualized Cancer Immunotherapy Field
September 24, 2026
Mise à disposition du Rapport Financier Semestriel au 30 juin 2026
September 23, 2026
Transgene and ProBioGen Expand Strategic Partnership with Additional License Agreement for AGE1.CR.pIX Cell Line
September 8, 2026
Transgene étend son partenariat stratégique avec ProBioGen par un nouvel accord de licence pour la lignée cellulaire AGE1.CR.pIX
September 7, 2026
Transgene and Nec Report 100% Three-Year Disease-Free Survival with TG4050 and Publish Phase 1 Results in Nature Communications
September 2, 2026
Transgene et NEC annoncent 100 % de survie sans récidive après 3 ans de suivi avec TG4050 et publient les résultats de la Phase 1 dans Nature Communications
September 1, 2026
Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of June 30, 2026
July 7, 2026
Bilan du Contrat de Liquidité avec la Société Natixis Oddo BHF SCA au 30 juin 2026
July 6, 2026
Transgene présente des données précliniques de son vaccin innovant contre le mpox produit sur lignée cellulaire, TG-MVA
June 24, 2026
Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine
June 22, 2026
Transgene’s Combined General Meeting of May 22, 2026
May 22, 2026
Availability of Preparatory Documents for the Combined General Meeting of May 22, 2026
May 4, 2026
Transgene Provides Business and Financial Update for Q1 2026
April 29, 2026
Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
April 13, 2026
Availability of Transgene’s 2025 Universal Registration Document (URD)
April 9, 2026
Transgene to Participate in Upcoming Investor Meetings
April 7, 2026
Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer
April 2, 2026
Transgene to Deliver an Oral Presentation on its Individualized Neoantigen Therapeutic Vaccine TG4050 at the World Vaccine Congress
March 26, 2026
Transgene Continues Progress to Reshape Early-Stage Cancer Treatment through Individualized Neoantigen Therapeutic Vaccines (INTV) Backed by Financial Visibility Until Early 2028
March 24, 2026
Transgene Announces Financial Calendar for 2026
February 4, 2026
Transgene Further Strengthens Scientific Advisory Board with Appointments of Renowned Cancer Immunotherapy Experts Antoine Italiano and Ignacio Melero
January 23, 2026
Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2025
January 12, 2026
Transgene Publishes Phase I Data Supporting TG4050’s Potential in Preventing Head and Neck Cancer Relapse
January 9, 2026
Transgene announces the resume of trading of its shares on Euronext Paris as of the opening of the markets
November 26, 2025
Transgene Successfully Completes a Fundraising of c. €105 Million
November 26, 2025
Correction: Transgene Announces the Temporary Suspension of Trading of its Shares on Euronext Paris
November 25, 2025
Transgene Announces the Temporary Suspension of Trading of its Shares on Euronext Paris
November 25, 2025
Correction: Transgene launches a fundraising campaign for approximately 105 million euros
November 25, 2025
Transgene launches a fundraising campaign for approximately 105 million euros
November 25, 2025
Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool to Optimize Individualized Therapeutic Cancer Vaccines
November 6, 2025
Transgene Provides Business and Financial Update for Q3 2025
November 4, 2025
Transgene to Present New Immunological Data from Phase I Trial of Individualized Therapeutic Cancer Vaccine, TG4050, at SITC 2025
October 3, 2025
Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive Randomized Phase I Data Randomization to be Completed in Phase II Part in Q4 2025
September 16, 2025
Societe Generale: shares & voting rights as of 31 August 2025
September 9, 2025
Transgene Appoints Seasoned Industry Executive Emmanuelle Quilès to Board of Directors as Independent Director
July 9, 2025
Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of June 30, 2025
July 8, 2025
Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial in Operable Head and Neck Cancer
June 19, 2025
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
June 13, 2025
Transgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presented at ASCO 2025
June 3, 2025
Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccine TG4050
June 1, 2025
Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025
May 22, 2025
Transgene's Combined General Meeting of May 15, 2025
May 15, 2025